Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid

Gut

Volumn 54, Issue 7, 2005, Pages 955-959

  Llopis, M ^a   Antolin M ^a   Guarner, F ^a   Salas, A ^b   Malagelada, J R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOPEROXIDASE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL TRANSLOCATION; COLITIS; CONTROLLED STUDY; ENZYME ACTIVITY; INFLAMMATION; INTESTINE FLORA; LACTOBACILLUS CASEI; LIVER; MALE; MESENTERY LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN;

ANIMALS; BACTERIAL TRANSLOCATION; COLITIS, ULCERATIVE; COLON; DISEASE MODELS, ANIMAL; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; LACTOBACILLUS CASEI; LIVER; LYMPH NODES; MALE; PEROXIDASE; PROBIOTICS; RATS; RATS, SPRAGUE-DAWLEY; SPLEEN; TRINITROBENZENESULFONIC ACID;

EID: 21044459650     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.056101     Document Type: Article

References (27)

1. Morris GP, Beck PL, Herridge MS, et al. Hopten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803.
2. Yamada T, Marshall S, Specian RD, et al. A comparative analysis of two models of colitis in rats. Gastroenterology 1992;102:1524-34.
3. Okayasu I, Hotokeyomo S, Yomodo M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
4. Little JR, Eisen HN. Preparation and characterization of antibodies specific for the 2,4,6-trinitrophenyl group. Biochemistry 1966;5:3385-95.
5. Kunin S, Gollily R. Recognition and lysis of altered self cells by macrophages, o modification of target cells by 2,4,6-trinitrobenzene sulfonic acid. Immunology 1983;121:1711-18.
6. Tatsumi Y, Lichtenberger LM. Molecular association of trinitrobenzenesulfonic acid and surface phospholipids in the development of colitis in rats. Gastroenterology 1996;110:780-9.
7. García-Lafuente A, Antolín M, Guarner F, et al. Incrimination of anaerobic bacteria in the induction of experimental colitis. Am J Physiol 1997;272:G10-1.
8. Borruel N, Carol M, Casellas F, et al. Increased mucosal TNFα production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659-64.
9. Borruel N, Casellas F, Antolín M, et al. Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol 2003;98:865-70.
10. Nicklas W, Baneux P, Boot R, et al. Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 2002;36:20-42.
11. Morton DB, Griffiths PHM, Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Veterinary Record April 20, 1985. For reference No 11, do you have any more details? Volume number? Page numbers?.
12. Favia R, Willen R, Ar'Rajab A, et al. Acetic acid-induced colitis in the rat: a reproducible experimental model for acute ulcerative colitis. Eur Surg Res 1992;24:211-25.
13. Mainous MR, Tso P, Berg RD, et al. Studies of the route, magnitude, and time course of bacterial translocation in a model of systemic inflammation. Arch Surg 1991;126:33-7.
14. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr 2001;73(suppl):399-405S.
15. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-14.
16. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580-91.
17. Schulte M, Veltkomp C, Dielemon LA, et al. Loctobacillus plontorum 299V in the treatment and prevention of spontaneous colitis in interleukin-10- deficient mice. Inflamm Bowel Dis 2002;8:71-80.
18. McCarthy J, O'Mohony L, O'Collaghan L, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin-10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975-80.
19. Kennedy RJ, Hoper M, Deodhar K, et al. Probiotic therapy fails to improve gut permeability in a hapten model of colitis. Scond J Gastroenterol 2000;35:1266-71.
20. Pavan S, Desreumoux P, Mercenier A. Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of loctic acid bacteria. Clin Diagn Lab Immunol 2003;10:696-701.
21. Bernet MF, Brossart D, Neeser JR, et al. Lactobocillus acidophilus LA1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994;35:483-9.
22. Mack DR, Michail S, Wei S, et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999;276:G941-50.
23. García-Lafuente A, Antolín M, Guarner F, et al. Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut 2001;48:503-7.
24. Chapat L, Chemin K, Dubois B, et al. Lactobacillus cosei reduces CD8+ T cell-mediated skin inflammation. Eur J Immunol 2004;34:2520-8.
25. Menard S, Condalh C, Bombou JC, et al. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 2004;53:821-8.
26. Sheil B, McCorthy J, O'Mohony L, et al. Is the mucosol route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004;53:694-700.
27. Obermeier F, Dunger N, Strouch UG, et al. Contrasting activity of cytosin-guonosin dinucleotide oligonucleotides in mice with experimental colitis. Clin Exp Immunol 2003;134:217-24.